Leukemia/Lymphoma Phenotyping by Flow Cytometry
Ordering Recommendation
Aids in the diagnosis of hematopoietic neoplasms.
Flow Cytometry
1-2 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Bone marrow. Whole blood: Green (sodium heparin), lavender (EDTA), or pink (K2EDTA). Tissue or fluid.  
Specimen Preparation
Transport 1 mL heparinized bone marrow (Min: 0.5 mL*) OR 5 mL whole blood (Min: 1mL*) OR 100 mg fresh tissue suspended in tissue culture media (e.g., RPMI 1640)
(Min: 100 mg*) OR 10-100 mL fresh fluid (Min: 3 mL*).*Minimum volume is dependent on cellularity.  
Storage/Transport Temperature
Specimen should be received within 24 hours of collection for optimal cell viability.
Bone marrow or whole blood:
Room temperature. Also acceptable: Refrigerated.
Tissue or fluid:
Unacceptable Conditions
Unacceptable Conditions: Frozen, clotted or hemolyzed specimens.  
A minimum of 10,000 viable cells is required for flow cytometry phenotyping of samples containing a very limited number of markers (may also be called antibodies or antigens). For low-count specimens, supplying clinical and diagnostic
information is especially important to help ensure that the most appropriate marker combinations are evaluated before the specimen is depleted of cells.
Bone marrow or whole blood:
Provide specimen source, CBC, Wright stained smear (if available), clinical history, differential diagnosis, and any relevant pathology reports.
Tissue or fluid:
Provide specimen source, clinical history, differential diagnosis, and any relevant pathology reports.
Follow up:
If previous leukemia/lymphoma phenotyping was performed at another lab, the outside flow cytometry report and histograms (if possible) should accompany the specimen.  
Stability (collection to initiation of testing): Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
By Report  
Interpretive Data
By Report

See Compliance Statement A: www.aruplab.com/CS
Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
Flow cytometric leukemia and lymphoma analysis may aid in identifying the tumor lineage for diagnostic and prognostic purposes. After review of the clinical history and morphology, a panel of markers is selected for each case by a board-certified pathologist. In most cases, the lineage can be identified as T-cell, B-cell, or myeloid and a diagnosis or differential diagnosis can be made. 

Available Markers*:

CD1, CD2, CD3, CD4, CD5, CD7, CD8, TCR alpha-beta, TCR gamma-delta, Cytoplasmic CD3
CD10, CD19, CD20, CD22, CD23, CD103, Kappa, Lambda, FMC7, Cytoplasmic Kappa, Cytoplasmic Lambda
CD11b, CD13, CD14 (Mo2), CD14 (MY4), CD15, CD33, CD64, CD117, myeloperoxidase
CD11c, CD16, CD25, CD30, CD34, CD38, CD41, CD42b, CD45, CD56, CD57, CD61, HLA-DR, glycophorin, TdT, bcl-2, ALK-1, CD123, CD138, CD200, CD26, CD45.

*Not all markers will be reported in all cases.
Requests for specific markers to be run must be listed on manual requisition or by footnote for electronic orders. We do not offer individual marker identification separately outside of the markers in this panel.

A comprehensive flow cytometric Leukemia/Lymphoma assessment of tissue, fluid, or peripheral blood typically includes 15 or more markers; a bone marrow evaluation typically includes 22 or more markers. At the discretion of the pathologist, limited-cellularity samples (CSF, tissue/fluids) will be triaged and an appropriate number of markers will be run due to the irreplaceable nature of these samples. Limited-cellularity samples typically include a minimum number of markers (e.g., 7-15 markers).

The report will include a pathologist interpretation and a marker interpretation range corresponding to CPT codes of 2-8 markers, 9-15 markers, and 16+ markers interpreted. Charges apply per marker.
CPT Code(s)
88184, 88185 each additional marker; 88187 or 88188 or 88189.
Component Test Code*Component Chart Name
0092286Number Of Markers
2008004Leuk/Lymph Phenotype, % CD2
2008005Leuk/Lymph Phenotype, % CD3
2008006Leuk/Lymph Phenotype, % CD4
2008007Leuk/Lymph Phenotype, % CD5
2008008Leuk/Lymph Phenotype, % CD7
2008009Leuk/Lymph Phenotype, % CD8
2008010Leuk/Lymph Phenotype, % CD25
2008011Leuk/Lymph Phenotype, % Alpha-Beta
2008012Leuk/Lymph Phenotype, % Gamma-Delta
2008013Leuk/Lymph Phenotype, % CD1
2008014Leuk/Lymph Phenotype, % Cytoplasmic CD3
2008015Leuk/Lymph Phenotype, % CD16
2008016Leuk/Lymph Phenotype, % CD56
2008017Leuk/Lymph Phenotype, % CD57
2008018Leuk/Lymph Phenotype, % CD10
2008019Leuk/Lymph Phenotype, % CD19
2008020Leuk/Lymph Phenotype, % CD20
2008021Leuk/Lymph Phenotype, % CD21
2008022Leuk/Lymph Phenotype, % CD22
2008023Leuk/Lymph Phenotype, % CD23
2008024Leuk/Lymph Phenotype, % CD24
2008025Leuk/Lymph Phenotype, % Kappa
2008026Leuk/Lymph Phenotype, % Lambda
2008027Leuk/Lymph Phenotype, % CD103
2008028Leuk/Lymph Phenotype, % CD11c
2008029Leuk/Lymph Phenotype, % FMC7
2008030Leuk/Lymph Phenotype, % Cyto Kappa
2008031Leuk/Lymph Phenotype, % Cyto Lambda
2008032Leuk/Lymph Phenotype, % bcl-2
2008033Leuk/Lymph Phenotype, % CD30
2008034Leuk/Lymph Phenotype, % CD34
2008035Leuk/Lymph Phenotype, % HLA-DR
2008036Leuk/Lymph Phenotype, % CD11b
2008037Leuk/Lymph Phenotype, % CD13
2008038Leuk/Lymph Phenotype, % CD14 (MO2)
2008039Leuk/Lymph Phenotype, % CD14 (MY4)
2008040Leuk/Lymph Phenotype, % CD15
2008041Leuk/Lymph Phenotype, % CD18
2008042Leuk/Lymph Phenotype, % CD33
2008043Leuk/Lymph Phenotype, % CD64
2008044Leuk/Lymph Phenotype, % CD117
2008045Leuk/Lymph Phenotype, % Myeloperoxidase
2008046Leuk/Lymph Phenotype, % CD9
2008047Leuk/Lymph Phenotype, % CD41
2008048Leuk/Lymph Phenotype, % CD42b
2008049Leuk/Lymph Phenotype, % CD61
2008050Leuk/Lymph Phenotype, % Glycophorin
2008051Leuk/Lymph Phenotype, % CD38
2008052Leuk/Lymph Phenotype, % TdT
2008053Leuk/Lymph Phenotype, % ALK-1
2008054Leuk/Lymph Phenotype, % CD123
2008055Leuk/Lymph Phenotype, % CD138
2008056Leuk/Lymph Phenotype, % CD200
2008057Leuk/Lymph Phenotype, % CD26
2008058Leuk/Lymph Phenotype, % CD45
2008059Leuk/Lymph Phenotype, Impression
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Chronic Lymphocytic Leukemia Follow up Phenotyping by Flow Cytometry
  • Follow-Up Phenotyping
  • Hematopoietic neoplasms monitoring
  • Leukemia/Lymphoma Evaluation Panel
  • Leukemia/Lymphoma Phenotyping, Comprehensive-Bone Marrow
  • Leukemia/Lymphoma Phenotyping, Comprehensive-Miscellaneous
  • Leukemia/Lymphoma Phenotyping, Comprehensive-Whole Blood
  • Neoplastic Mature T-Cell Evaluation by Flow Cytometry